Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Clear all
Completed Phase 2 Interventional

CT 327 in the Treatment of Psoriasis Vulgaris

NCT00995969
View directory record Official record
Conditions
Psoriasis
Interventions
placebo, CT 327
Drug
Lead sponsor
Creabilis SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Charlotte, North Carolina • Wilmington, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

NCT02905331
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Ocala, Florida • Rolling Meadows, Illinois • Plainfield, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

NCT07024602
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ASC50 tablets or matching placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 9:47 AM EDT
Completed No phase listed Observational

Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis

NCT02162472
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 4 Interventional Results available

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

NCT03055494
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
Hot Springs, Arkansas • Los Angeles, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis

NCT00419666
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Calcitriol 3mcg/g
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Little Rock, Arkansas • San Diego, California • Eagan, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 25, 2026, 9:47 AM EDT
Terminated No phase listed Observational

UCB Cimzia Pregnancy Follow-up Study

NCT02775656
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 25, 2026, 9:47 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis

NCT04571151
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LEXETTE 0.05% Topical Foam, Sorilux 0.005 % Topical Foam, Vehicle Foam
Drug · Other
Lead sponsor
Skin Sciences, PLLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Can We Miss Pigmented Lesions in Psoriasis Patients?

NCT01053819
View directory record Official record
Conditions
Psoriasis, Melanoma, Non-melanoma Skin Cancer
Interventions
etanercept
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

NCT01555125
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
secukinumab 150 mg, secukinumab 300 mg, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 25, 2026, 9:47 AM EDT
Not listed Phase 1Phase 2 Interventional

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

NCT01670513
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Low Strength, IDP-118 High Strength
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Santa Rosa, California • Clinton Township, Michigan • Fort Gratiot, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 25, 2026, 9:47 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

OTIS Cimzia Pregnancy Registry

NCT01797224
View directory record Official record
Conditions
Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
925 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis

NCT00941278
View directory record Official record
Conditions
Psoriasis
Interventions
PH-10 (0.001% Rose Bengal)
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2010 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

NCT00126724
View directory record Official record
Conditions
Arthritis, Rheumatoid, Arthritis, Psoriatic, Ankylosing Spondylitis
Interventions
tgAAC94 gene therapy vector, tgAAC94 placebo
Genetic
Lead sponsor
Targeted Genetics Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
22
States / cities
Glendale, Arizona • Tuscon, Arizona • Palm Desert, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2009 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

NCT02494479
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Prurisol, Placebo
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Huntsville, Alabama • Encino, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 25, 2026, 9:47 AM EDT
Withdrawn No phase listed Observational

Evaluation of Vitamin D Levels in Psoriasis Patients

NCT01903317
View directory record Official record
Conditions
Psoriasis
Interventions
Topical Therapy, Phototherapy and Systemic Therapy, Biologic Therapy
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 3 Interventional

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00691964
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ABT-874, etanercept, placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02514577
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-122 Lotion, IDP-122 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Hot Springs, Arkansas • Encinitas, California • Encino, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

NCT01490632
View directory record Official record
Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
Interventions
Placebo, Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)

NCT02187172
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Ustekinumab, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
23
States / cities
Tuscaloosa, Alabama • Denver, Colorado • Trumbull, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 25, 2026, 9:47 AM EDT
Not listed Not applicable Interventional

Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis

NCT03817164
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Autonomic Nerve Modulation - Active, Autonomic Nerve Modulation - Control
Device
Lead sponsor
Thync Global, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 25, 2026, 9:47 AM EDT
Active, not recruiting Phase 2 Interventional

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

NCT03886246
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Auburn Hills, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 25, 2026, 9:47 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis

NCT01873677
View directory record Official record
Conditions
Psoriasis
Interventions
M518101, Vehicle
Drug
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
31
States / cities
Mobile, Alabama • Phoenix, Arizona • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 25, 2026, 9:47 AM EDT